II. Indications

III. Mechanism

  1. Semisynthetic glucosaminoglycan

IV. Dosing

  1. Pentosan polysulfate 100 mg PO tid

V. Efficacy

  1. Symptoms improve as much as 50% in controlled trials
  2. Response may not be seen for 3 to 6 months

VI. Adverse Effects

  1. Diarrhea
  2. Dyspepsia
  3. Alopecia (reversible)
  4. Headache
  5. Rash
  6. Dizziness
  7. Abdominal Pain
  8. Liver function abnormalities (<4%)
  9. Retinal damage (Pigmentary Maculopathy)
    1. Retinal pigment changes result in Blurred Vision and difficulty in adjusting to dim lighting
    2. Risk increases with prolonged use (25% of patients using Elmiron >15 years)
    3. Dilated Eye Exam is recommended for patients on Elmiron
    4. Pearce (2018) Ophthalm 125(11): 1793-802 [PubMed]
    5. (2018) presc lett 27(2): 10

VII. References

  1. Bade (1997) Br J Urol 79:168-71
  2. Parsons (1993) J Urol 150:845-8

Images: Related links to external sites (from Bing)

Related Studies

Cost: Medications

elmiron (on 4/19/2017 at Medicaid.Gov Survey of pharmacy drug pricing)
ELMIRON 100 MG CAPSULE $7.98 each

Ontology: Elmiron (C0600293)

Concepts Pharmacologic Substance (T121) , Carbohydrate (T118)
MSH D010426
English pentosan polysulfate sodium (Elmiron), elmiron, Elmiron

Ontology: Pentosan Polysulfate (C0600296)

Definition (NCI_NCI-GLOSS) A drug used to relieve pain or discomfort associated with chronic inflammation of the bladder. It is also being evaluated for its protective effects on the gastrointestinal tract in people undergoing radiation therapy.
Definition (NCI) A semisynthetic heparin-like glucosaminoglycan. Although its mechanism of action is unknown, pentosan polysulfate may act as a buffer to control cell permeability by preventing irritating solutes from reaching cells coated with it. Administered orally, excreted pentosan polysulfate adheres to the urinary bladder wall, preventing irritants from entering bladder cells and the development or progression of interstitial cystitis (IC), a complication of some chemotherapies. This agent also exhibits anticoagulant and fibrinolytic properties. (NCI04)
Concepts Pharmacologic Substance (T121) , Carbohydrate (T118)
MSH D010426
SnomedCT 109116008, 372571007
English Polysulfate, Pentosan, pentosan polysulphate, pentosanpolysulfate, pentosan polysulfate, PENTOSAN POLYSULFATE, Pentosan polysulfate (product), Pentosan polysulfate (substance), Pentosan polysulfate, Pentosan polysulphate, Xylan Hydrogen Sulfate, Xylan Polysulfate, Pentosan Polysulfate
Portuguese Pentosana Polissulfato
Spanish Pentosan Polisulfato, polisulfato de pentosan (sustancia), pentosano polisulfato, pentosano polisulfato (sustancia), polisulfato de pentosan, polisulfato de pentosano, polisulfato de pentosano (producto), pentosano polisulfato (producto), polisulfato de pentosano (sustancia)
German Pentosanpolysulfat